RHF1A Antibody

What is RHF1A antibody and what specific protein does it target?

RHF1A antibody is a rat monoclonal antibody (clone 20A8; IgG2a isotype) specifically designed to recognize and bind to iRhom1 proteins. The antibody was developed using standard immunization procedures and shows high specificity for iRhom1 without significant cross-reactivity to the related iRhom2 protein when used in properly controlled experimental settings. This antibody has been validated through comparative analysis in wild-type mouse embryonic fibroblasts (mEFs) versus knockout models lacking iRhom1 (iR1KO), demonstrating its specificity and utility in research applications .

How can researchers distinguish between RHF1A detection of iRhom1 versus potential cross-reactivity with other proteins?

To ensure specific detection of iRhom1 and eliminate potential cross-reactivity concerns, researchers should implement multiple validation controls. The gold standard approach involves parallel analysis of samples from wild-type tissues alongside tissues from iRhom1 knockout models. Any signal detected in knockout samples would indicate potential cross-reactivity. Additionally, researchers should consider pre-absorption controls where the antibody is pre-incubated with purified target protein before application to samples. Signal reduction after pre-absorption indicates specific binding. Finally, comparing results with alternative antibodies targeting different epitopes of iRhom1 can provide confirmatory evidence of specificity .

What are the optimal Western blot conditions for RHF1A antibody detection of endogenous iRhom1?

For optimal Western blot detection of endogenous iRhom1 using RHF1A antibody, researchers should implement the following protocol:

• Protein extraction: Use RIPA buffer supplemented with protease inhibitors, maintaining cold conditions throughout.

• Sample preparation: Load 20-40μg protein per lane after denaturation (95°C for 5 minutes).

• Electrophoresis: Separate proteins on 8-10% SDS-PAGE.

• Transfer: Use PVDF membrane with semi-dry transfer (15V for 60 minutes).

• Blocking: 5% non-fat milk in TBST for 1 hour at room temperature.

• Primary antibody: Dilute RHF1A antibody 1:1000 in blocking solution, incubate overnight at 4°C.

• Washing: 3 × 10 minutes with TBST.

• Secondary antibody: Anti-rat IgG-HRP at 1:5000 for 1 hour at room temperature.

• Development: Use enhanced chemiluminescence with exposure times typically between 30 seconds to 5 minutes .

This methodology has been validated to reproducibly detect iRhom1 in mouse embryonic fibroblasts when appropriate controls are included.

How can RHF1A antibody be applied in cell surface biotinylation studies?

RHF1A antibody has been successfully employed in cell surface biotinylation studies to detect the membrane-associated fraction of iRhom1. The recommended protocol includes:

• Wash adherent cells (80-90% confluence) three times with ice-cold PBS.

• Incubate cells with Sulfo-NHS-SS-Biotin (0.5mg/ml in PBS) for 30 minutes at 4°C.

• Quench excess biotin with 50mM Tris-HCl (pH 7.5) for 10 minutes.

• Lyse cells with RIPA buffer containing protease inhibitors.

• Incubate lysates with streptavidin-agarose beads overnight at 4°C.

• Wash beads extensively and elute bound proteins.

• Analyze eluted proteins by Western blotting using RHF1A antibody.

This method allows specific analysis of the cell surface population of iRhom1, as demonstrated in studies with wild-type mouse embryonic fibroblasts .

How can researchers utilize RHF1A antibody to investigate the relationship between iRhom1 and ADAM17?

Investigating the functional relationship between iRhom1 and ADAM17 requires a multi-faceted approach where RHF1A antibody plays an essential role. Researchers should:

• Compare iRhom1 protein levels in wild-type versus ADAM17-knockout cells using RHF1A antibody in Western blot analysis.

• Perform co-immunoprecipitation studies with RHF1A antibody to assess physical interactions between iRhom1 and ADAM17.

• Conduct subcellular fractionation followed by RHF1A immunoblotting to determine if ADAM17 affects iRhom1 localization.

• Implement pulse-chase experiments with RHF1A immunoprecipitation to examine whether ADAM17 influences iRhom1 protein stability.

Research has shown that iRhom1 levels appear slightly increased in ADAM17-deficient mouse embryonic fibroblasts, suggesting a potential regulatory relationship between these proteins that warrants further investigation .

What approaches can be used to investigate potential functional redundancy between iRhom1 and iRhom2 using RHF1A antibody?

To investigate potential functional redundancy between iRhom1 and iRhom2, researchers can implement the following experimental strategy utilizing both RHF1A antibody (for iRhom1) and complementary iRhom2 antibodies:

• Comparative expression analysis: Quantify relative expression levels of iRhom1 and iRhom2 across different tissues and developmental stages using Western blot with RHF1A antibody and anti-iRhom2 antibodies.

• Single and double knockout studies: Analyze phenotypic consequences in iRhom1-knockout, iRhom2-knockout, and double-knockout models, with protein verification using appropriate antibodies.

• Compensatory expression: Examine whether iRhom1 levels (detected with RHF1A antibody) increase in iRhom2-knockout models and vice versa.

• Rescue experiments: Test whether overexpression of iRhom1 can rescue phenotypes in iRhom2-knockout models and vice versa.

Research indicates that iRhom1 levels were not significantly altered in iRhom2-knockout mouse embryonic fibroblasts, suggesting potential independent functions rather than compensatory mechanisms in this cellular context .

What are the most common causes of inconsistent RHF1A antibody performance in Western blot applications?

When researchers encounter inconsistent results with RHF1A antibody in Western blot applications, several factors may contribute:

• Sample preparation issues:

  • Inadequate protein extraction (particularly for membrane proteins)

  • Protein degradation during sample processing

  • Insufficient denaturation of complex membrane proteins

• Technical factors:

  • Suboptimal antibody dilution (1:1000 typically recommended)

  • Inadequate blocking (5% milk in TBST for 1-2 hours recommended)

  • Insufficient washing between antibody incubations

• Protein-specific considerations:

  • Post-translational modifications affecting epitope accessibility

  • Variable expression levels across different cell types/conditions

  • Protein-protein interactions masking antibody binding sites

To address these issues, researchers should systematically optimize each variable while maintaining appropriate positive and negative controls (including iRhom1-knockout samples) to ensure reliable and reproducible results .

How should researchers interpret variations in iRhom1 protein size detected by RHF1A antibody?

When RHF1A antibody detects iRhom1 proteins of varying molecular weights, researchers should consider:

• Post-translational modifications: Glycosylation, phosphorylation, and ubiquitination can significantly alter the apparent molecular weight of iRhom1.

• Proteolytic processing: iRhom1 may undergo partial proteolysis during cell signaling or sample preparation, resulting in detection of fragments.

• Alternative splicing: Different iRhom1 isoforms may exist due to alternative splicing of the transcript.

• Experimental artifacts: Incomplete denaturation or protein-protein interactions that persist through SDS-PAGE can cause mobility shifts.

To distinguish between these possibilities, researchers should implement:

• Deglycosylation experiments using PNGase F

• Phosphatase treatment to remove phosphate groups

• Comparison with recombinant iRhom1 protein standards

• Analysis of mRNA transcripts to identify potential splice variants

Careful interpretation of these variations can provide insights into iRhom1 biology and potential regulatory mechanisms .

How can RHF1A antibody be combined with other methodologies to study iRhom1's role in the ubiquitin-proteasome system?

Integrating RHF1A antibody with complementary techniques enables comprehensive analysis of iRhom1's role in the ubiquitin-proteasome system:

• Ubiquitination analysis:

  • Immunoprecipitate iRhom1 using RHF1A antibody, followed by immunoblotting with anti-ubiquitin antibodies

  • Alternatively, precipitate ubiquitinated proteins and probe for iRhom1 using RHF1A antibody

• Proteasome inhibition studies:

  • Treat cells with proteasome inhibitors (MG132, bortezomib)

  • Monitor iRhom1 levels using RHF1A antibody to assess degradation dynamics

• In vitro ubiquitination assays:

  • Reconstitute ubiquitination systems with purified components

  • Detect ubiquitination of iRhom1 substrates using specific antibodies

• Proximity ligation assays:

  • Combine RHF1A antibody with antibodies against ubiquitin system components

  • Visualize protein interactions in situ

This integrated approach is particularly relevant given the known function of RHF1a protein as a RING-finger E3 ligase that targets proteins for proteasome-mediated degradation .

What are the most effective strategies for combining RHF1A antibody-based protein detection with transcriptional analysis of iRhom1?

Researchers seeking to correlate iRhom1 protein levels with transcript expression should consider these methodological approaches:

• Parallel analysis workflow:

  • Split samples for simultaneous protein extraction and RNA isolation

  • Quantify iRhom1 protein using RHF1A antibody in Western blot or ELISA formats

  • Measure transcript levels using RT-qPCR or RNA-seq

  • Perform correlation analysis between protein and mRNA levels

• Cell-type specific analysis:

  • Implement single-cell approaches combining immunostaining with RHF1A antibody and RNA in situ hybridization

  • Alternatively, use flow cytometry to sort cell populations followed by parallel protein and RNA analysis

• Temporal dynamics studies:

  • Conduct time-course experiments following stimulation or developmental progression

  • Track both protein levels (via RHF1A antibody) and transcript levels at each timepoint

• Translational regulation investigation:

  • Combine polysome profiling with RHF1A immunoblotting to assess translational efficiency

Research has demonstrated that iRhom1 transcripts are detected in most developmental stages during gametogenesis, providing a basis for comparative protein-transcript analyses .

How might RHF1A antibody facilitate research into the evolutionary conservation of iRhom1 function across species?

RHF1A antibody can serve as a valuable tool for evolutionary studies of iRhom1 through:

• Cross-species reactivity testing:

  • Evaluate RHF1A antibody binding to iRhom1 orthologs across model organisms

  • Develop conservation maps of the recognized epitope

• Comparative expression profiling:

  • Use RHF1A antibody (if cross-reactive) or species-specific equivalents to compare expression patterns

  • Correlate with functional conservation analysis

• Domain-function relationships:

  • Compare protein interactions detected by co-immunoprecipitation with RHF1A antibody across species

  • Identify conserved versus divergent interaction partners

• Structural biology integration:

  • Combine epitope mapping of RHF1A antibody with structural analysis of iRhom1

  • Use antibody binding to inform structure-function relationships

This work would build upon current understanding that RHF1a and its homologs appear to be plant-specific proteins with important conserved functions in development, suggesting evolutionary divergence of these regulatory pathways .

What methodological advances might enhance the utility of RHF1A antibody for in vivo imaging and functional studies?

Future methodological developments to enhance RHF1A antibody applications may include:

• Antibody engineering approaches:

  • Fragment-based derivatives (Fab, scFv) for improved tissue penetration

  • Site-specific conjugation with fluorophores or nanoparticles for advanced imaging

  • Bispecific formats targeting iRhom1 and functional partners simultaneously

• Intrabody applications:

  • Modified RHF1A antibody formats for intracellular expression

  • Fusion with subcellular targeting sequences for compartment-specific studies

  • Integration with proximity-based labeling systems (BioID, APEX)

• In vivo imaging adaptations:

  • Near-infrared fluorophore conjugation for deep-tissue imaging

  • PET/SPECT-compatible radiolabeling for whole-organism studies

  • Photoacoustic imaging compatibility

• Therapeutic research applications:

  • Investigation of antibody-mediated modulation of iRhom1 function

  • Development of conditional protein degradation systems utilizing RHF1A-derived binding modules

These advancements would significantly expand the research applications of RHF1A antibody beyond its current utility in Western blotting and immunoprecipitation studies .

How does RHF1A antibody performance compare with polyclonal antibodies targeting iRhom1?

The performance characteristics of monoclonal RHF1A antibody versus polyclonal anti-iRhom1 antibodies can be summarized as follows:

For critical experiments, researchers may benefit from using both antibody types in parallel to leverage their complementary strengths. Studies have shown that polyclonal antibodies against the cytoplasmic domain of iRhom2 were not reproducibly effective for Western blot detection, highlighting the value of well-characterized monoclonal antibodies like RHF1A .

What considerations should guide the selection between RHF1A antibody and molecular genetic approaches to study iRhom1 function?

When designing experiments to investigate iRhom1 function, researchers must carefully consider the relative advantages of antibody-based versus genetic approaches:

• Temporal resolution considerations:

  • RHF1A antibody: Detects endogenous protein at precise time points

  • Genetic approaches: Allow manipulation of expression but with potential delays

• Spatial resolution capabilities:

  • RHF1A antibody: Can detect subcellular localization with immunostaining

  • Genetic approaches: Can provide tissue-specific manipulation with appropriate promoters

• Functional impact assessment:

  • RHF1A antibody: Primarily observational unless used for blocking functions

  • Genetic approaches: Direct manipulation of expression levels or protein function

• Technical limitations:

  • RHF1A antibody: Limited by epitope accessibility and fixation sensitivity

  • Genetic approaches: Subject to compensation, developmental effects, and off-target concerns

A comprehensive research program would ideally integrate both approaches, using RHF1A antibody for protein detection and localization while employing CRISPR/Cas9 or RNAi for functional studies. This integration has proven valuable in studies of the related RHF1a E3 ligase, where both protein detection and genetic manipulation provided complementary insights into its role in gametogenesis .

What experimental design principles should guide researchers using RHF1A antibody in developmental biology studies?

When applying RHF1A antibody in developmental biology research, investigators should adhere to these design principles:

• Establish clear temporal sampling frameworks:

  • Define precise developmental stages for analysis

  • Implement consistent collection protocols for comparable results

  • Consider time-course analyses to capture dynamic changes

• Incorporate appropriate controls:

  • Age-matched wild-type controls

  • Genetic knockouts for antibody validation

  • Developmental stage-specific positive controls

• Apply multi-scale analysis approaches:

  • Tissue-level expression (Western blotting with RHF1A)

  • Cellular resolution (immunohistochemistry)

  • Subcellular localization (immunofluorescence with co-markers)

• Integrate with functional assays:

  • Correlate protein expression with phenotypic outcomes

  • Design interference experiments to test functional hypotheses

  • Consider rescue experiments to confirm specificity

These principles align with established practices in developmental biology research, as demonstrated in studies of RHF1a in plant gametogenesis, where transcript analysis was conducted across multiple developmental stages .

How should researchers design experiments to investigate potential post-translational modifications of iRhom1 using RHF1A antibody?

To effectively investigate post-translational modifications (PTMs) of iRhom1, researchers should implement a systematic experimental design:

• PTM-specific sample preparation:

  • Phosphorylation: Include phosphatase inhibitors during extraction

  • Ubiquitination: Add deubiquitinase inhibitors and proteasome inhibitors

  • Glycosylation: Preserve native conditions during initial extraction

• Modification-specific analyses:

  • Two-dimensional gel electrophoresis followed by RHF1A immunoblotting

  • Immunoprecipitation with RHF1A followed by PTM-specific antibodies

  • Mass spectrometry analysis of immunoprecipitated iRhom1

• Functional correlation experiments:

  • Site-directed mutagenesis of predicted modification sites

  • Treatment with modification-inducing stimuli followed by RHF1A detection

  • Temporal analysis of modifications during signaling cascades

• Validation approaches:

  • In vitro enzymatic assays with purified components

  • Pharmacological inhibitors of specific modification enzymes

  • Genetic models with PTM pathway alterations